180 Life Sciences Corporate Media Kit

13 • Common localized fibrotic condition of the hand, develops over years • Nodules form under skin – eventually creating a thick cord pulling one or more fingers • Can limit hand functions • Unlike liver and lung fibrosis can be identified early Early disease Late disease – results in impaired hand function No approved treatment: unmet need Our trial is in early disease (1) Current treatment options suboptimal: (2) • Surgery – long (3 month) recovery, 6% recurrence at 5yr • Needle perforation – less invasive, 30% recurrence at 5yr • Collagenase injections – office procedure, 47% recurrence at 5yr Initial Indication Targeting Dupuytren’s Disease (1) Approval only from MHRA/CCMO and relevant accredited ethics committees. (2) Layton T & Nanchahal J. F1000Research 2019, 8(F1000Faculty Rev): 231 180 Life Sciences Corp. www.180lifesciences.com Q4 2020